Dexcom Inc
DXCM66.060USD
+0.150+0.23%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
25.76BMarket Cap
35.86P/E TTM
More Details of Dexcom Inc Company
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
Dexcom Inc Info
Ticker SymbolDXCM
Company nameDexcom Inc
IPO dateApr 14, 2005
CEOMr. Jacob Steven (Jake) Leach
Number of employees10300
Security typeOrdinary Share
Fiscal year-endApr 14
Address6340 Sequence Drive
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18582000200
Websitehttps://www.dexcom.com/
Ticker SymbolDXCM
IPO dateApr 14, 2005
CEOMr. Jacob Steven (Jake) Leach
Company Executives of Dexcom Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jacob Steven (Jake) Leach
Mr. Jacob Steven (Jake) Leach
President, Interim Principal Executive Officer, Chief Operating Officer, Director
President, Interim Principal Executive Officer, Chief Operating Officer, Director
294.46K
+6.59%
Mr. Mark G. Foletta
Mr. Mark G. Foletta
Interim Independent Chairman of the Board
Interim Independent Chairman of the Board
62.13K
+4.65%
Mr. Steven R. (Steve) Altman
Mr. Steven R. (Steve) Altman
Independent Director
Independent Director
61.05K
+4.13%
Mr. Richard Alexander Collins
Mr. Richard Alexander Collins
Independent Director
Independent Director
44.38K
+5.82%
Mr. Nicholas (Nick) Augustinos
Mr. Nicholas (Nick) Augustinos
Independent Director
Independent Director
42.13K
+6.12%
Mr. Jereme M. Sylvain
Mr. Jereme M. Sylvain
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
35.33K
-12.01%
Ms. Bridgette P. Heller
Ms. Bridgette P. Heller
Independent Director
Independent Director
27.03K
-3.61%
Mr. Kyle Malady
Mr. Kyle Malady
Independent Director
Independent Director
22.67K
-2.86%
Ms. Rimma Driscoll
Ms. Rimma Driscoll
Independent Director
Independent Director
9.04K
+127.87%
Ms. Renee D. Gala
Ms. Renee D. Gala
Independent Director
Independent Director
6.88K
+20.30%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jacob Steven (Jake) Leach
Mr. Jacob Steven (Jake) Leach
President, Interim Principal Executive Officer, Chief Operating Officer, Director
President, Interim Principal Executive Officer, Chief Operating Officer, Director
294.46K
+6.59%
Mr. Mark G. Foletta
Mr. Mark G. Foletta
Interim Independent Chairman of the Board
Interim Independent Chairman of the Board
62.13K
+4.65%
Mr. Steven R. (Steve) Altman
Mr. Steven R. (Steve) Altman
Independent Director
Independent Director
61.05K
+4.13%
Mr. Richard Alexander Collins
Mr. Richard Alexander Collins
Independent Director
Independent Director
44.38K
+5.82%
Mr. Nicholas (Nick) Augustinos
Mr. Nicholas (Nick) Augustinos
Independent Director
Independent Director
42.13K
+6.12%
Mr. Jereme M. Sylvain
Mr. Jereme M. Sylvain
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
35.33K
-12.01%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Distributor
977.80M
84.50%
Direct
179.30M
15.50%
By RegionUSD
Name
Revenue
Proportion
United States
841.00M
72.68%
Outside of United states
316.10M
27.32%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Distributor
977.80M
84.50%
Direct
179.30M
15.50%
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
12.63%
BlackRock Institutional Trust Company, N.A.
6.24%
State Street Investment Management (US)
4.32%
Baillie Gifford & Co.
4.07%
Geode Capital Management, L.L.C.
2.81%
Other
69.92%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
12.63%
BlackRock Institutional Trust Company, N.A.
6.24%
State Street Investment Management (US)
4.32%
Baillie Gifford & Co.
4.07%
Geode Capital Management, L.L.C.
2.81%
Other
69.92%
Shareholder Types
Shareholders
Proportion
Investment Advisor
53.37%
Investment Advisor/Hedge Fund
28.82%
Hedge Fund
7.32%
Research Firm
4.05%
Pension Fund
2.14%
Bank and Trust
1.94%
Sovereign Wealth Fund
1.61%
Venture Capital
0.48%
Individual Investor
0.37%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
2120
388.08M
103.93%
+205.32K
2025Q3
2198
388.02M
104.56%
+4.65M
2025Q2
2236
383.14M
106.39%
+1.38M
2025Q1
2227
382.03M
104.52%
-27.81M
2024Q4
2209
376.25M
104.20%
-2.27M
2024Q3
2125
380.57M
105.64%
-16.02M
2024Q2
2097
395.55M
99.88%
+7.96M
2024Q1
2075
388.09M
102.93%
-19.55M
2023Q4
2061
396.17M
102.99%
+6.26M
2023Q3
1969
388.25M
103.58%
-414.67K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
48.15M
12.28%
+859.71K
+1.82%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
24.25M
6.18%
-475.12K
-1.92%
Jun 30, 2025
State Street Investment Management (US)
16.86M
4.3%
+175.27K
+1.05%
Jun 30, 2025
Baillie Gifford & Co.
16.71M
4.26%
+2.53M
+17.81%
Jun 30, 2025
Geode Capital Management, L.L.C.
10.77M
2.75%
+358.62K
+3.45%
Jun 30, 2025
Jennison Associates LLC
11.52M
2.94%
+994.30K
+9.45%
Jun 30, 2025
Invesco Capital Management (QQQ Trust)
8.03M
2.05%
-28.35K
-0.35%
Aug 31, 2025
Nuveen LLC
7.30M
1.86%
-549.07K
-7.00%
Jun 30, 2025
MFS Investment Management
6.49M
1.65%
+3.30M
+103.55%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Global X Internet of Things ETF
3.86%
iShares U.S. Medical Devices ETF
2.71%
Motley Fool Global Opportunities ETF
1.9%
First Trust Growth Strength ETF
1.74%
Putnam Sustainable Future ETF
1.61%
First Trust NASDAQ-100 Ex-Technology Sector Index Fund
1.51%
Invesco S&P 500 Equal Weight Health Care ETF
1.25%
Direxion NASDAQ-100 Equal Weighted Index Shares
0.83%
First Trust NASDAQ 100 Equal Weighted Index Fund
0.83%
iShares Russell Mid-Cap Growth ETF
0.7%
View more
Global X Internet of Things ETF
Proportion3.86%
iShares U.S. Medical Devices ETF
Proportion2.71%
Motley Fool Global Opportunities ETF
Proportion1.9%
First Trust Growth Strength ETF
Proportion1.74%
Putnam Sustainable Future ETF
Proportion1.61%
First Trust NASDAQ-100 Ex-Technology Sector Index Fund
Proportion1.51%
Invesco S&P 500 Equal Weight Health Care ETF
Proportion1.25%
Direxion NASDAQ-100 Equal Weighted Index Shares
Proportion0.83%
First Trust NASDAQ 100 Equal Weighted Index Fund
Proportion0.83%
iShares Russell Mid-Cap Growth ETF
Proportion0.7%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 28, 2022
Split
1→4
Date
Type
Ratio
Mar 28, 2022
Split
1→4
FAQs
Who are the top five shareholders of Dexcom Inc?
The top five shareholders of Dexcom Inc are:
The Vanguard Group, Inc. holds 48.15M shares, accounting for 12.28% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 24.25M shares, accounting for 6.18% of the total shares.
State Street Investment Management (US) holds 16.86M shares, accounting for 4.30% of the total shares.
Baillie Gifford & Co. holds 16.71M shares, accounting for 4.26% of the total shares.
Geode Capital Management, L.L.C. holds 10.77M shares, accounting for 2.75% of the total shares.
The Vanguard Group, Inc. holds 48.15M shares, accounting for 12.28% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 24.25M shares, accounting for 6.18% of the total shares.
State Street Investment Management (US) holds 16.86M shares, accounting for 4.30% of the total shares.
Baillie Gifford & Co. holds 16.71M shares, accounting for 4.26% of the total shares.
Geode Capital Management, L.L.C. holds 10.77M shares, accounting for 2.75% of the total shares.
What are the top three shareholder types of Dexcom Inc?
The top three shareholder types of Dexcom Inc are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
How many institutions hold shares of Dexcom Inc (DXCM)?
As of 2025Q4, 2120 institutions hold shares of Dexcom Inc, with a combined market value of approximately 388.08M, accounting for 103.93% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.63%.
What is the biggest source of revenue for Dexcom Inc?
In FY2025Q2, the Distributor business generated the highest revenue for Dexcom Inc, amounting to 977.80M and accounting for 84.50% of total revenue.
